Alto Neuroscience, Inc. (ANRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alto Neuroscience, Inc. (ANRO) has a cash flow conversion efficiency ratio of -0.076x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.52 Million) by net assets ($151.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Alto Neuroscience, Inc. (ANRO) market capitalisation for the company's overall valuation and market capitalisation.
Alto Neuroscience, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Alto Neuroscience, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alto Neuroscience, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alto Neuroscience, Inc. ranked by their cash flow conversion efficiency. See debt repayment capacity of Alto Neuroscience, Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunan Tyen Machinery Co Ltd A
SHG:600698
|
-0.044x |
|
Crossamerica Partners LP
NYSE:CAPL
|
-0.355x |
|
New Wave Group AB (publ)
ST:NEWA-B
|
0.078x |
|
Treasure ASA
OL:TRE
|
0.012x |
|
Zhejiang Jingxing Paper Joint Stock Co Ltd
SHE:002067
|
0.019x |
|
ZKTECO Co. Ltd. A
SHE:301330
|
N/A |
|
PixArt Imaging
TWO:3227
|
0.057x |
|
VNDIRECT Securities Corp
VN:VND
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Alto Neuroscience, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Alto Neuroscience, Inc. from 2021 to 2025. View latest Alto Neuroscience, Inc. stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $151.14 Million | $-51.77 Million | -0.343x | -9.39% |
| 2024-09-30 | $151.46 Million | $-47.42 Million | -0.313x | -167.09% |
| 2023-09-30 | $-71.67 Million | $-33.45 Million | 0.467x | -12.11% |
| 2022-09-30 | $-38.41 Million | $-20.39 Million | 0.531x | -28.46% |
| 2021-09-30 | $-12.48 Million | $-9.26 Million | 0.742x | -- |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more